Search clinical trials for: Algoplus® scale

Total 22801 results

National Center for Research Resources (NCRR)

Unknown

Cognitive Aspects of Adolescent Suicide

Suicide, Attempted

United States
Memorial Sloan Kettering Cancer Center

Completed

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

Breast Cancer | Atrophic Vaginitis

United States
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.; Autoimmunity Centers of Excellence

Completed

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Systemic Lupus Erythematosus (SLE) | Multiple Sclerosis (MS) | Rheumatoid Arthritis (RA) | Juvenile Dermatomyositis (JDM) | Juvenile Idiopathic Arthritis (JIA) | Pemphigus Vulgaris | Systemic Sclerosis (SSc) | Pediatric SLE | Pediatric-Onset Multiple Sclerosis (POMS)

United States
St. Jude Children's Research Hospital

Terminated

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Hematological Malignancies

United States
Mayo Clinic

Recruiting

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
Takeda

Active, not recruiting

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic

Active, not recruiting

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Plasmacytoma | POEMS Syndrome

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Leukemia

United States, Australia, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Lymphoma

Lymphoma

United States, Australia, Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma

Glioblastoma | Malignant Glioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Recurrent Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Lung Squamous Cell Carcinoma
Rashmi Verma, MD
National Cancer Institute (NCI)

Recruiting

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States, Saudi Arabia, Puerto Rico
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Disease | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Adult B Acute Lymphoblastic... and other conditions

United States
Abdullah Khan

Terminated

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

Meningioma | Low Grade Glioma | Malignant Brain Neoplasm | Malignant Brain Glioma

United States
Newcastle-upon-Tyne Hospitals NHS Trust
National Institute for Health Research, United Kingdom; Alder Hey Children's...

Recruiting

Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP) (AIR:RRP)

Human Papilloma Virus | Recurrent Respiratory Papillomatosis

United Kingdom
University of California, San Diego
Leadiant Biosciences, Inc.

Terminated

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Acute Lymphocytic Leukemia | Adult Lymphoblastic Lymphoma

United States
University of Rochester NCORP Research Base
National Cancer Institute (NCI)

Completed

Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

Breast Carcinoma

United States
University of Vigo
Hospital Clinico Universitario de Santiago; Xunta de Galicia; Ministerio de Educacion...

Completed

Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy (MAPEC)

Hypertension

Spain
Ohio State University Comprehensive Cancer Center

Recruiting

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
University of Washington
Genzyme, a Sanofi Company

Recruiting

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Active, not recruiting

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Sanofi

Active, not recruiting

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

AL Amyloidosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Terminated

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Renal Failure | Plasma Cell Myeloma

United States
Mayo Clinic

Completed

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Washington
Bayer

Terminated

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Non-Hodgkin's Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Grade 3b Follicular Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Plasmacytoma | Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Systemic Mastocytosis | Recurrent... and other conditions

United States
Elvira Umyarova
Sanofi

Recruiting

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Martin Huelsmann

Recruiting

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Heart Diseases | Diabetes Mellitus, Type 2

New Zealand, Austria, Netherlands, Spain, United Kingdom
Abdullah Khan

Recruiting

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular... and other conditions

United States
HTL-Strefa S.A.

Completed

Capillary Blood Volume and Pain Perception Obtained in a Process of Puncturing With Different Safety Lancets

Healthy

Poland
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Multiple Myeloma | ISS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

AL Amyloidosis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

Locally Advanced Sarcoma

United States
Anne Noonan

Active, not recruiting

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Bile Duct Cancer | Gall Bladder Cancer | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage II Colon Cancer | Stage... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States

Search clinical trials for: Algoplus® scale

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations